Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
GAGalectin Therapeutics Inc. logo

Galectin Therapeutics Inc. (GALT)

NASDAQ Capital Market · Currency in USD
$3.19 ▼ -0.19 (-5.62%)
At close: Oct 23, 4:00 PM ET. Market closed.
$3.19 ▲ +0.00 (+0.00%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$3.38
Open
$3.33
Day's Range
$3.16 – $3.37
52 Week Range
$2.03 – $7.13
Volume
195,180
Avg. Volume
554,543
Market Cap
$210.08M
Beta (5Y Monthly)
0.38
PE Ratio (TTM)
--
EPS (TTM)
-$0.42
Earnings Date
Nov 13, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$11.00

Profile: Galectin Therapeutics Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
9
CEO
Joel Lewis

Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring linked to fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis, alongside its potential for cancer treatment.

Earnings

Next report: Fri, Nov 13, 2026
EPS estimate -$0.05
DateEst.Actual
Aug 14, 2026-$0.09-$0.14Miss
May 15, 2026-$0.06-$0.08Miss
Mar 31, 2026-$0.10-$0.08Beat
Nov 14, 2025-$0.11-$0.13Miss
Aug 14, 2025-$0.16-$0.12Beat
May 15, 2025-$0.20-$0.15Beat

Analyst view

Consensus price target
$11.00 ▲ +244.8%
Range $11.00 – $11.00
Rating: Buy
Buy 82% · Hold 18% · Sell -0%

Get free alerts on GALT and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.